Mothers after Gestational Diabetes in Australia (MAGDA): A Randomised Controlled Trial of a Postnatal Diabetes Prevention Program

This study evaluated a specific lifestyle modification program designed to prevent type 2 diabetes in women who had previously experienced gestational diabetes (GDM).

The **intervention** was a structured, group-based lifestyle modification program, delivered over a 12-month period. It consisted of:

One initial individual session.

Five group sessions, typically delivered over a three-month period.

Two follow-up telephone sessions, conducted at six and nine months after the start of the program.

The program's content was adapted from the Greater Green Triangle Diabetes Prevention Program (GGT-DPP) to specifically address the needs and barriers faced by mothers in their first postnatal year. The overall aim was to promote changes in anthropometric (body measurements), behavioral (lifestyle), and biomedical (blood markers) outcomes.

The **comparator** was "usual care." This means the control group received the standard postnatal care typically provided to mothers in Australia, without any specific diabetes prevention program or structured lifestyle intervention from the study. This allows researchers to see if the intervention adds benefit beyond what women would normally experience.

The **outcome measures** were categorized into primary and secondary outcomes:

**Primary Outcomes (measured at 12 months):**

**Body weight:** Measured in kilograms (kg).

**Waist circumference:** Measured in centimeters (cm).

**Fasting blood glucose:** Measured in millimoles per liter (mmol/l). These three measures are key indicators of diabetes risk.

**Secondary Outcomes:**

**Achievement of lifestyle modification goals:** While not explicitly detailed in the abstract, this would typically involve metrics related to diet quality, physical activity levels, and other health behaviors promoted by the program.

**Changes in depression score:** This suggests the program also aimed to address mental well-being, potentially using a standardized questionnaire like the Patient Health Questionnaire 9 (PHQ-9) which is mentioned in the abbreviations list.

**Changes in cardiovascular disease risk factors:** This would likely include other blood markers such as cholesterol levels (e.g., HDL-C, LDL-C, mentioned in abbreviations) and blood pressure, though specific details are not provided in the abstract.

The study included **573 women** in total.

**Intervention group:** 284 women.

**Usual care group:** 289 women.

The **population** studied consisted of:

Women aged 18 years or older.

All participants had a diagnosis of gestational diabetes mellitus (GDM) in their most recent pregnancy. GDM was defined by Australasian Diabetes in Pregnancy Society (ADIPS) criteria: a fasting plasma glucose (FPG) of 5.5 mmol/l or higher, or a 2-hour glucose of 8.0 mmol/l or higher on a 75-g oral glucose tolerance test (OGTT), or a glucose challenge test result of 11.1 mmol/l or higher.

Participants were recruited during their first postnatal year, meaning the intervention was offered relatively soon after childbirth.

At baseline, 10% of the women had impaired glucose tolerance (IGT) and 2% had impaired fasting glucose (IFG), indicating that the majority had near-normal glucose metabolism profiles at the start of the study, despite their history of GDM. This is important because it means their risk was elevated due to GDM history, but not yet at the pre-diabetes stage for most.

**Exclusion criteria** included:

Preexisting diabetes (type 1 or type 2).

Cancer (not in remission).

Severe mental illness.

Substance abuse (illicit drugs).

Myocardial infarction in the preceding 3 months.

Difficulty with English.

Involvement in another postnatal intervention trial.

Pregnancy at baseline testing or at any point during the 12 months of study involvement (women who became pregnant during the study were excluded from the primary outcome analysis due to the impact pregnancy would have on weight, waist circumference, and fasting glucose).

The **setting** for the study was multicenter, recruiting women from two Australian state capital cities: Melbourne and Adelaide.

The study measured key health indicators to assess the effectiveness of the diabetes prevention program. While the abstract does not provide exhaustive detail on every instrument, it implies standard clinical and self-report methods:

**Body Weight:** Measured in kilograms (kg). This would typically be done using a calibrated scale, with participants wearing light clothing and no shoes, to ensure accuracy and consistency.

**Waist Circumference:** Measured in centimeters (cm). This is usually taken at a specific anatomical landmark (e.g., midway between the lower rib margin and the iliac crest, or at the narrowest part of the torso), using a non-stretchable measuring tape. Standardized procedures are crucial for reliable measurements.

**Fasting Blood Glucose:** Measured in millimoles per liter (mmol/l). This involves a blood sample taken after an overnight fast (typically 8-12 hours). The blood is then analyzed in a laboratory using standard enzymatic methods to determine glucose concentration. This is a direct and objective measure of blood sugar control.

**Depression Score:** Although not explicitly stated how it was measured in the abstract, the "PHQ-9" (Patient Health Questionnaire 9) is listed in the abbreviations. The PHQ-9 is a widely used, self-administered questionnaire for screening, diagnosing, monitoring, and measuring the severity of depression. It consists of nine questions that correspond to the diagnostic criteria for major depressive disorder. Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

**Cardiovascular Disease Risk Factors:** The abbreviations mention "HDL-C" (high-density lipoprotein cholesterol) and "LDL-C" (low-density lipoprotein cholesterol). These would be measured via blood tests, typically as part of a lipid panel, also after an overnight fast. These are objective biochemical markers.

**Achievement of Lifestyle Modification Goals:** This would likely involve self-reported questionnaires or diaries related to dietary intake (e.g., frequency of healthy foods, portion sizes) and physical activity levels (e.g., minutes of moderate-intensity exercise per week). While self-report can be subject to bias, it's a common way to assess behavioral changes in lifestyle interventions.

The use of objective measures like weight, waist circumference, and fasting blood glucose, alongside potentially validated questionnaires for depression and self-reported lifestyle goals, provides a comprehensive picture of the program's impact.

The MAGDA study was designed as a **multicentre, prospective, open randomised controlled trial (RCT)**. This is considered the gold standard for evaluating the effectiveness of interventions because it minimizes bias and allows for strong conclusions about cause and effect.

**How they ran the study:**

1. **Recruitment:** Women were recruited from two Australian cities (Melbourne and Adelaide) using multiple strategies, both prospective (identifying eligible women as they were diagnosed with GDM) and retrospective (contacting women with a past GDM diagnosis).

2. **Eligibility Screening:** Women were screened based on age, GDM diagnosis in their most recent pregnancy, and various exclusion criteria (e.g., pre-existing diabetes, current pregnancy, severe mental illness).

3. **Baseline Assessment:** After enrollment, participants underwent baseline measurements for primary and secondary outcomes (weight, waist circumference, fasting blood glucose, etc.).

4. **Randomisation:** A total of 573 eligible women were **randomised** into one of two groups:

* **Intervention group (n = 284):** Received the structured lifestyle modification program.

* **Usual care group (n = 289):** Received standard postnatal care.

Randomisation is a critical step in an RCT. It involves assigning participants to groups purely by chance (e.g., using a computer algorithm). The **WHY** this design matters is that it aims to create groups that are, on average, similar in all characteristics at the start of the study, including both known and unknown factors that might influence the outcomes. This means that any differences observed between the groups at the end of the study are more likely to be due to the intervention itself, rather than pre-existing differences between the participants.

5. **Intervention Delivery:** The intervention group participated in the program over 12 months, comprising one individual session, five group sessions, and two telephone sessions. The usual care group continued with their standard postnatal care.

6. **Duration:** The study followed participants for **12 months**. This duration is important because lifestyle changes and their impact on metabolic health often take time to manifest. A 12-month period allows for a reasonable assessment of sustained changes and their effects on diabetes risk factors.

7. **Follow-up Assessments:** At the end of the 12-month period, primary and secondary outcomes were measured again for both groups.

8. **Statistical Approach:** The primary analysis used an **intention-to-treat (ITT)** approach. The **WHY** this matters is that ITT analysis includes all participants in the groups to which they were originally randomised, regardless of whether they completed the intervention or dropped out. This approach reflects real-world effectiveness, as not everyone will fully adhere to a program. It also helps to preserve the benefits of randomisation and provides a more conservative estimate of the intervention's effect, preventing overestimation of efficacy that might occur if only highly adherent participants were analyzed.

**Blinding:**

The study was described as an "open" RCT. This means it was **not blinded**.

**Participants** knew whether they were receiving the intervention or usual care.

**Researchers/providers